Cell therapy overview

The book is comprised of five sections with part I covering systemic and endoluminal therapy with an incisive overview of hemostasis and thrombosis part II covers local therapy with several chapters devoted to drug-eluting stents and restenosis therapies part III covers cell therapy and therapeutic angiogenesis and includes chapters on cell transplantation and clinical trials in cellular therapy part IV covers adjunctive pharmacotherapy with chapters devoted to various patient populations including those with heart failure, diabetes, atrial fibrillation, peripheral artery disease,... 

Here, an overview of biopharmaceutical products thus far approved (within the EU and US at least) is presented. The products have been grouped into nine categories recombinant blood factors, recombinant thrombolytics, recombinant insulins, additional recombinant hormones, recombinant hematopoietic growth factors, recombinant IFNs and ILs, recombinant vaccines, monoclonal and engineered antibodies, and additional biopharmaceuticals (e.g., cell therapy, gene therapy, siRNA). 

Expanded hematopoietic (stem and progenitor) cells have widespread potential in therapy and this will only be briefly described here. For a comprehensive overview, the review by Schindhelm and Nordon [27] is recommended. Potential applications include graft engineering in stem cell transplantation [24], gene and immunotherapy and the production of mature blood cells for transfusion medicine. 

For additional information, reference may be made to the volume by Life Extension Foundation (2003). It should also be mentioned that this volume has the following chapter or section titles Cancer Overview of Protocols Cancer Adjuvant Therapies Cancer Chemotherapy Cancer Clinics Offering Alternative Therapies and Cancer Gene Therapies, Stem Cells, Telomeres, and Cytokines. There are also chapters or sections titled Cancer Prevention Cancer Radiation Therapy ... 

Lorigan P, Woll PJ, O Brien ME, et al (2005) Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst 97 666-674 McArthur HE, Hudis CA (2007) Dose-dense therapy in the treatment of early-stage breast cancer an overview of the data. Clin Breast Cancer 8(suppl 1) S6-S10 Norton L (2005) Conceptual and practical implications of breast tissue geometry toward a more effective, less toxic therapy. Oncologist 10 370-381 Orzano JA, Swain SM (2005) Concepts and clinical trials of dose-dense chemotherapy for breast cancer. Clin Breast Cancer 6 402-411... 

Antibiotic activity and channel replacement therapies are two areas where synthetic ion transport systems show potential. Other applications include drug delivery, chemical sensing, cell signaling, organocatalysis, and material science. The examples of synthetic ion transporters reviewed provide an overview of the successful designs and combinations of ion receptor interactions used to facilitate transmembrane transport. In this regard, important advances have been made in the last decade. There is little doubt that real-world application of these systems will come in the near future. 

---